Clinical Research Directory
Browse clinical research sites, groups, and studies.
Safety and Efficacy of Autologous iNSC-DAP in the Treatment of Parkinson's Disease
Sponsor: Xuanwu Hospital, Beijing
Summary
This is a phase I, interventional, single arm, open-label, clinical study to evaluate the safety and efficacy of the striatal transplantation of autologous induced neural stem cell-derived DA precursor cells in Parkinson's Disease patients.
Official title: Safety and Efficacy of Autologous Induced Neural Stem Cell-derived Dopaminergic Precursor Cells in the Treatment of Parkinson's Disease
Key Details
Gender
All
Age Range
30 Years - 85 Years
Study Type
INTERVENTIONAL
Enrollment
10
Start Date
2023-06-13
Completion Date
2026-12-31
Last Updated
2023-06-22
Healthy Volunteers
No
Conditions
Interventions
Autologous induced neural stem cell-derived DA precursor cells
The autologous induced neural stem cell-derived DA precursor cells will be stereotactically implanted into the striatum of PD patients.
Locations (1)
Xuanwu Hospital Capital Medical University
Beijing, Beijing Municipality, China